ArticleGynecologic oncology reports2025
Extragonadal immature teratoma of the uterus.
Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: With fewer than 20 cases of extragonadal teratomas since 1929, treatment guidelines remain unclear. Case Presentation: A 27-year-old nulliparous female presented with vaginal bleeding and malodorous discharge. Transvaginal ultrasound and pelvic MRI revealed a 4 cm prolapsing echogenic cervical mass that was FDG avid on PET CT. Biopsy confirmed a grade 1 polypoid immature teratoma arising from either the uterus or cervix. She underwent a total laparoscopic hysterectomy, bilateral salpingectomy, omentectomy, and primary optimal tumor debulking to R0. Bilaterally ovaries appeared grossly normal and were preserved. On final pathology, the patient was staged using FIGO ovarian cancer criteria as Stage IIIA2 grade 2 immature teratoma of the uterus. The patient received three cycles of bleomycin, etoposide, and cisplatin. The patient is 11 months post-surgery and currently undergoing surveillance. Conclusion: Given the rarity of uterine immature teratomas, management of this case was extrapolated from existing recommendations for immature ovarian teratomas. Unlike in prior case reports where surgical approach was via an exploratory laparotomy, our patient underwent optimal debulking via minimally invasive surgery with ovarian preservation and adjuvant chemotherapy. Given the chemosensitive nature of germ cell tumors, further fertility sparing options for extragonadal immature teratoma may be further explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.